Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stuart A Grossman

Showing results (1-10 of 171) with videos related to

Pageof 18
Sort By:
Neuro-Oncology|October 19, 2020
The duration of adjuvant temozolomide in patients with glioblastoma and the law of diminishing returnsStuart A Grossman
Seminars in Oncology|February 7, 2004
Arguments against the routine use of currently available adjuvant chemotherapy in high-grade gliomasStuart A Grossman
Neuro-Oncology|March 7, 2023
Using historical objective response rates to design single-arm phase II trials in patients with recurrent glioblastomaStuart A Grossman
The Journal of Supportive Oncology|October 19, 2011
Challenges in supportive care of patients with neoplastic meningitisMatthias Holdhoff, Stuart A Grossman
Current Treatment Options in Oncology|June 10, 2011
Treatment of glioblastoma in "elderly" patientsSusannah Yovino, Stuart A Grossman
Handbook of Clinical Neurology|January 11, 2012
Chemotherapy with cytotoxic and cytostatic agents in brain cancerJaishri Blakeley, Stuart A Grossman
Neuro-Oncology|September 1, 2017
A search for the "Goldilocks zone" with regard to the optimal duration of adjuvant temozolomide in patients with glioblastomaStuart A Grossman, Lawrence Kleinberg
CNS Oncology|July 6, 2013
Severity, etiology and possible consequences of treatment-related lymphopenia in patients with newly diagnosed high-grade gliomasSusannah Yovino, Stuart A Grossman
The Oncologist|February 23, 2011
Controversies in the adjuvant therapy of high-grade gliomasMatthias Holdhoff, Stuart A Grossman
British Journal of Cancer|September 9, 2015
Comment on 'Dexamethasone exerts profound immunologic interference on treatment efficacy for recurrent glioblastoma'Susannah Ellsworth, Stuart A Grossman
Pageof 18

Showing results (1-10 of 171) with videos related to

Sort By:
Pageof 18
Neuro-Oncology|October 19, 2020
The duration of adjuvant temozolomide in patients with glioblastoma and the law of diminishing returnsStuart A Grossman
Seminars in Oncology|February 7, 2004
Arguments against the routine use of currently available adjuvant chemotherapy in high-grade gliomasStuart A Grossman
Neuro-Oncology|March 7, 2023
Using historical objective response rates to design single-arm phase II trials in patients with recurrent glioblastomaStuart A Grossman
The Journal of Supportive Oncology|October 19, 2011
Challenges in supportive care of patients with neoplastic meningitisMatthias Holdhoff, Stuart A Grossman
Current Treatment Options in Oncology|June 10, 2011
Treatment of glioblastoma in "elderly" patientsSusannah Yovino, Stuart A Grossman
Handbook of Clinical Neurology|January 11, 2012
Chemotherapy with cytotoxic and cytostatic agents in brain cancerJaishri Blakeley, Stuart A Grossman
Neuro-Oncology|September 1, 2017
A search for the "Goldilocks zone" with regard to the optimal duration of adjuvant temozolomide in patients with glioblastomaStuart A Grossman, Lawrence Kleinberg
CNS Oncology|July 6, 2013
Severity, etiology and possible consequences of treatment-related lymphopenia in patients with newly diagnosed high-grade gliomasSusannah Yovino, Stuart A Grossman
The Oncologist|February 23, 2011
Controversies in the adjuvant therapy of high-grade gliomasMatthias Holdhoff, Stuart A Grossman
British Journal of Cancer|September 9, 2015
Comment on 'Dexamethasone exerts profound immunologic interference on treatment efficacy for recurrent glioblastoma'Susannah Ellsworth, Stuart A Grossman
Pageof 18